3D Medicines Inc.

Equities

1244

KYG8872R1011

Biotechnology & Medical Research

Market Closed - Hong Kong S.E. Other stock markets 04:08:28 2024-05-24 am EDT			5-day change	1st Jan Change
7.43 ^HKD	+6.45%		-1.07%	-2.75%

Mar. 29	3D Medicines' 2023 Loss Almost Halves as Revenue Jumps 12%	MT
Mar. 28	3D Medicines Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

3D Medicines Inc. has filed an IPO in the amount of HKD 429.023996 million.

November 29, 2022 at 12:00 am EST

3D Medicines Inc. has filed an IPO in the amount of HKD 429.023996 million.

Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 1,635,000
PriceRange: HKD 22.96 to HKD 26.24
Discount Per Security: HKD 0.615

Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 8,941,273
PriceRange: HKD 22.96 to HKD 26.24
Discount Per Security: HKD 0.615

Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 5,773,727
PriceRange: HKD 22.96 to HKD 26.24
Discount Per Security: HKD 0.615

Transaction Features: Regulation S; Rule 144A; Sponsor Backed Offering

Latest news about 3D Medicines Inc.

3D Medicines' 2023 Loss Almost Halves as Revenue Jumps 12%	Mar. 29	MT
3D Medicines Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
Simcere Pharmaceutical’s Profit to Fall Up to 27% in 2023	Feb. 19	MT
Simcere Pharmaceutical Expects Up to 26% Fall in 2023 Profit; Shares Slide 3%	Feb. 19	MT
3D Medicines Inc. commences an Equity Buyback Plan for 25,605,700 shares, representing 10% of its issued share capital, under the authorization approved on June 26, 2023.	Jan. 31	CI
Alphamab Oncology and 3Dmedicines Enters into A Licensing Agreement with Glenmark for KN035	Jan. 24	CI
Alphamab Oncology Unit, 3D Medicines Grants Glenmark Unit License to Commercialize Sarcoma Injectable	Jan. 24	MT
3D Medicines Unit Receives Repayment for 60 Million Yuan Loan	Jan. 22	MT
3D Medicines Subsidiary Extends 60 Million Yuan Loan; Shares Fall 3%	Jan. 04	MT
SELLAS Life Sciences Seeks Arbitration in Dispute with 3D Medicines	Dec. 27	MT
3D Medicines Inc. Announces Change of Principal Place of Business in Hong Kong	Dec. 26	CI
35,992,364 Ordinary Shares of 3D Medicines Inc. are subject to a Lock-Up Agreement Ending on 14-DEC-2023.	Dec. 13	CI
3D Medicines Gets US FDA's Nod to Trial Envafolimab; Shares Soar 24%	23-10-30	MT
3D Medicines Inc. Receives Approval from Fda to Proceed with Aglobal Phase Iii Trial for Treatment of the First Line Mismatch Repair ProficientAdvanced or Recurrent Endometrial Cancer	23-10-29	CI
Sellas Life Sciences Expects to Complete Patient Enrollment for Phase 3 REGAL Trial in November	23-10-12	MT
128,967,484 Ordinary Shares of 3D Medicines Inc. are subject to a Lock-Up Agreement Ending on 30-SEP-2023.	23-09-29	CI
3D Medicines Invests Over $21 Million of Surplus Cash	23-09-26	MT
3D Medicines Inc. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-25	CI
3D Medicines Raises HK$226.8 Million from Share Placement	23-07-21	MT
3D Medicines to Raise HK$232.2 Million from Share Placement	23-07-14	MT
3D Medicines Inc. announced that it expects to receive HKD 232.2 million in funding	23-07-13	CI
3D Medicines Expects Higher H1 Earnings	23-07-10	MT
3D Medicines Inc. Provides Earning Guidance for the Six Months Ended June 30, 2023	23-07-07	CI
74,330,404 Ordinary Shares of 3D Medicines Inc. are subject to a Lock-Up Agreement Ending on 14-JUN-2023.	23-06-13	CI
3D Medicines Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-30	CI

Chart 3D Medicines Inc.

Duration

Period

More charts

Company Profile

3D Medicines Biotechnology Shanghai Co Ltd is a China-based company mainly engaged in the research and development of commercial tumor products and candidate drugs. The Company's main product pipelines including an immuno-oncology monotherapy, drug candidates with mechanisms of action amenable to combination within the pipeline, and pain management assets. The Company's core product is subcutaneous injection of anti-PD-L1, envafolimab. The Company also has a number of candidate drugs in clinical stage, including peptide cancer vaccine 3D189, GAS6 decoy receptor 3D229, fibroblast growth factor receptor (FGFR) 3D185 and others. The Company mainly conducts its business in the domestic market.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
3D MEDICINES INC.	-2.75%	233M
VERTEX PHARMACEUTICALS INCORPORATED	+12.30%	118B
REGENERON PHARMACEUTICALS, INC.	+12.15%	106B
BIONTECH SE	-8.14%	23.4B
ARGENX SE	-1.69%	21.78B
GENMAB A/S	-10.60%	18.09B
WUXI APPTEC CO., LTD.	-41.25%	16.72B
BEIGENE, LTD.	-15.33%	15.97B
NEUROCRINE BIOSCIENCES, INC.	+5.80%	14.03B
SAREPTA THERAPEUTICS, INC.	+28.03%	11.67B

Bio Therapeutic Drugs